Literature DB >> 12141707

Cerebrotendinous xanthomatosis with psychiatric disorders: report of three siblings and literature review.

Yu Lee1, Pao-Yen Lin, Nien-Mu Chiu, Wen-Neng Chang, Jung-Kwang Wen.   

Abstract

Cerebrotendinous xanthomatosis (CTX), a rare familial lipid metabolic disease inherited via an autosomal recessive trait, is caused by mutations of the sterol 27-hydroxylase gene. Psychiatric disorders may occur in patients with CTX. In Taiwan, Chang et al presented patients with CTX. However, there has not been a case presented about CTX with psychiatric disorders in Taiwan. We present three siblings in one family with CTX combined with moderate mental retardation. One of the siblings had long-term depressed mood, irritability, poor appetite, insomnia, fatigability, and pessimistic thinking and was diagnosed as dysthymic disorder. After 2.5 years of antidepressant treatment at our outpatient clinic, the depressive symptoms of the dysthymic sibling improved greatly. However, the results of the IQ tests of the three siblings did not change after effective treatments for physical manifestations of CTX. In addition, the authors reviewed the literature of CTX combined with psychiatric disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12141707

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  10 in total

1.  Cerebrotendinous xanthomatosis.

Authors:  Mahalakshmi Muniaswamy; Madhu Rengasamy; Ramesh Aravamuthan; Manoharan Krishnasamy
Journal:  Indian Dermatol Online J       Date:  2016 Jul-Aug

2.  Cerebrotendinous xanthomatosis: a rare genetic disorder.

Authors:  Rohan Arjun Bhojwani; Rajashree Khot
Journal:  BMJ Case Rep       Date:  2011-09-05

3.  Cerebrotendinous xanthomatosis: a treatable hereditary neuro-metabolic disease.

Authors:  Ana Claudia Rodrigues de Cerqueira; Antônio Egídio Nardi; Jose Marcelo Ferreira Bezerra
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 4.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 5.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

6.  Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice.

Authors:  Chuang Wang; Jianrui Zhang; Yang Lu; Peipei Lin; Tonghe Pan; Xin Zhao; Aiming Liu; Qinwen Wang; Wenhua Zhou; Han-Ting Zhang
Journal:  Metab Brain Dis       Date:  2014-04-05       Impact factor: 3.584

7.  Cerebrotendinous xanthomatosis associated with immune thrombocytopenia.

Authors:  Noha M El Husseiny
Journal:  BMJ Case Rep       Date:  2010-11-05

Review 8.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

Review 9.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

Review 10.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.